中科信息公告，预计2026年净利润为1300万元—1550万元，同比增长35.73%—61.83%。报告期内，公 司预计归属于上市公司股东的净利润将实现同比增长，主要原因系公司市场拓展成效显著，完工交付项 目数量上升，带动营业收入及归属于上市公司股东净利润增长。 ...

证券代码：300678 证券简称：中科信息 公告编号：2026-002 中科院成都信息技术股份有限公司 2025 年度业绩预告 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 预计净利润为正值且属于下列情形之一： 扭亏为盈 同向上升 同向下降 | 项 | 目 | | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | | 盈利：1300 | 万元–1550 | 万元 | | 盈利：957.77 | 万元 | | 东的净利润 | | 比上年同期增长：35.73% | | - | 61.83% | | | | 扣除非经常性损益 | | 盈利：880 | 万元–1130 | 万元 | | 盈利：259.87 | 万元 | | 后的净利润 | | 比上年同期增长：238.63% | | - | 334.83% | | | 二、与会计师事务所沟通情况 公司就业绩预告有关事项与本公司 2025 年度报告审计机构信永中 和会计师事务所（特殊普通合伙）成都 ...

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Group 1 - The company, Zhongke Information, stated that its operations are currently normal [2] - Investors are advised to pay attention to future announcements regarding the company's performance in 2025 [2]

Core Insights - The article highlights that Zhongke Information Technology Co., Ltd. (referred to as "Zhongke Information") won the "2025 AI Innovation Application Award" at the 6th International Science and Technology Innovation Festival, showcasing its leading position in the integration of artificial intelligence and intelligent manufacturing [2][3]. Company Overview - Zhongke Information originated from the Computer Application Research Institute of the Chinese Academy of Sciences and has been engaged in AI research and application innovation since the 1990s, developing a comprehensive self-reliant technology system from hardware to software to systems [2]. - The company is led by a top-tier research team headed by Academician Zhang Jingzhong and focuses on the integration of production, education, and research to transform cutting-edge AI technologies into practical capabilities for industrial upgrades [2]. Product and Service Capabilities - Zhongke Information possesses dual capabilities in customized intelligent equipment and industrial software development, offering core products such as hyperspectral light sources, 8K intelligent cameras, and the EIOD edge intelligent industrial internet platform, which support the digital and intelligent transformation of manufacturing enterprises [3]. - The company is accelerating the development of the "AI + 'Dual Carbon'" platform, which aims to assist enterprises in achieving green and low-carbon transformations through carbon data transparency and intelligent emission reduction pathways [3]. Future Directions - The award-winning project focuses on building a "Future Factory" based on industrial multimodal data fusion and high-reliability output technology, developing a self-controllable industrial intelligent platform that enables a closed-loop empowerment from data perception to intelligent analysis and task execution [3]. - Zhongke Information aims to leverage the strong research foundation of the Chinese Academy of Sciences to deepen the integration of AI and manufacturing innovation, contributing to the construction of a self-controllable industrial intelligent system and promoting high-quality development of China's manufacturing industry [3].

Core Viewpoint - Zhongke Information's stock price has shown a significant increase of 16.64% year-to-date, despite a recent decline of 2.02% on January 15, with a current price of 35.88 CNY per share and a total market capitalization of 10.634 billion CNY [1] Financial Performance - For the period from January to September 2025, Zhongke Information reported a revenue of 194 million CNY, reflecting a year-on-year decrease of 11.22%, while the net profit attributable to shareholders was 4.5133 million CNY, down 27.07% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 81.3977 million CNY, with 39.5182 million CNY distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 16.28% to 48,900, while the average number of circulating shares per person increased by 19.34% to 5,945 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 2.9402 million shares, an increase of 1.6567 million shares from the previous period [3]

Core Viewpoint - The company, Zhongke Information, is a leading provider of AI-based industry information solutions in China, focusing on various sectors including smart governance, intelligent manufacturing, smart cities, and smart healthcare [1] Group 1: Company Overview - Zhongke Information was established through the transformation of the Chengdu Computer Application Research Institute of the Chinese Academy of Sciences and was listed on the Growth Enterprise Market in 2017 [1] - The company specializes in high-tech solutions utilizing core technologies such as high-speed machine vision and big data [1] Group 2: Key Focus Areas - The company provides comprehensive information solutions and intelligent engineering services in four main areas: - Smart Governance: Over 40 years of service to major national meetings with digital conference systems [1] - Intelligent Manufacturing: Covers the entire tobacco industry chain and offers the world's only AI detection solution for the entire printing process, as well as digital solutions for oil and gas fields [1] - Smart Cities: Develops economic, industrial, and statistical intelligence systems [1] - Smart Healthcare: Involves intelligent anesthesia robots and medical imaging-assisted diagnosis [1] Group 3: Industry Position - Zhongke Information is committed to advancing the industrialization of AI technology and fostering ecological cooperation within its sectors [1]

Core Viewpoint - The company has completed a full industry chain layout for "edge perception - digital middle platform - industry large model - industry application robot" and is accelerating the research and development of machine vision large models and industry-specific large models [1] Group 1: Industry Chain Layout - The company has launched the Zhongke Jiyun government affairs large model aimed at government agencies [1] - A multi-modal industrial inspection large model has been developed for industrial inspection scenarios [1] - The company has independently developed a medical large model to support the research and iteration of intelligent anesthesia robots [1] Group 2: Technological Applications - The models empower medical imaging analysis and tumor target delineation in diagnostic assistance [1] - The company plans to further strengthen internal common technology focus and technological collaboration [1] - The aim is to cover core business areas such as smart government affairs, intelligent manufacturing, and smart healthcare, providing technical support for product upgrades and digital transformation across various industries [1]

Core Viewpoint - Zhongke Information (300678) expects a significant increase in new contract value for 2025 compared to the previous year, driven by both recovery in existing business demand and growth in the Xinchuang (信创) sector [1] Group 1 - The company anticipates a substantial growth in new contracts for 2025 [1] - A portion of the new orders is attributed to the recovery of demand in existing business segments [1] - Another portion of the growth is linked to the incremental demand from the Xinchuang business [1]

Core Insights - The company, Zhongke Information, reported a significant increase in new contract value for 2025 compared to the previous year, driven by a recovery in demand and order growth in its existing business segments, as well as incremental growth from its Xinchuang business [1] Group 1 - The new contract value for 2025 is expected to see substantial growth compared to the previous year [1] - The growth in new contracts is attributed to both the recovery of existing business segments and the increase in orders [1] - The Xinchuang business is identified as a source of additional growth for the company [1]